Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on X by Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, adding:
“Huge thanks, Jean-Charles Soria for highlighting our Journal of Clinical Oncology commentary on the evolving understanding of ADCs – a complex, fascinating technology which is only at its dawn!”
Quoting Jean-Charles Soria’s post:
“ADCs are not just ‘guided missiles’ — new biology is reshaping how we view them.
Continuous payload exposure in circulation sustains cytotoxic thresholds.
Antigen level response: extracellular cleavage enables efficacy in ‘HER2-null’ tumors.
Fc functions and TME interactions may shape efficacy and toxicity (e.g., ILD, thrombocytopenia).
Cross-resistance across TOP1i ADCs → need for payload diversification.
Future: dual-payload ADCs, tumor-selective linkers, ADC–ICI combinations?”
Title: Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates
Journal: JCO
Authors: Matthew Vogel, Raffaele Colombo, and Paolo Tarantino
More from Paolo Tarantino on OncoDaily.